Why is Bright Minds Biosciences stock collapsing today?

Jefferies reduced its price target for Bright Minds Biosciences (DRUG) to $110 from $145, citing trial delays. The stock is down 37% in six months. Analysts maintain a Strong Buy consensus. The FDA issued a partial clinical hold on BMB-101 due to preclinical data concerns. The company reported Q3 2026 results, with mixed analyst reactions.

Baird reduced its price target for Bright Minds Biosciences (NASDAQ:DRUG) to $107 from $126 due to an FDA clinical hold, citing increased risk and delays. The stock trades at $20, well below its 52-week high. Despite the setback, the company maintains a 'GOOD' financial health score, with other analysts setting higher price targets. H.C. Wainwright reiterated a Buy rating with a $145 target.

Bright Minds Biosciences (NASDAQ:DRUG) received a partial FDA clinical hold on its BMB-101 Phase 2 epilepsy study due to toxicity concerns in mice and insufficient pediatric safety data. The hold affects only the US trial, not other ongoing studies. The company plans to discuss the issue with the FDA and may need additional preclinical data. BMB-101 showed promising results in earlier trials, but the FDA's concerns introduce regulatory uncertainty.

Bright Minds Biosciences (DRUG) reported a partial clinical hold by the FDA on its Phase 2 trial for BMB-101, a drug for developmental and epileptic encephalopathies (DEEs). The FDA cited toxicity concerns in mice and insufficient data. The company believes the hold is limited to the U.S. trial and does not affect other studies. DRUG stock fell 52.67% to $25.02.

Bright Minds Biosciences (NASDAQ:DRUG) shares fell 52% after the FDA placed its BMB-101 trial for epilepsy on partial clinical hold due to toxicity concerns in mice. The company believes the hold only affects the U.S. Phase 2 trial and plans to seek FDA clarification. Additional data or studies may be required to lift the hold.

The FDA partially halted Bright Minds Biosciences' planned Phase 2 trial for BMB-101, citing mouse toxicity and insufficient data. The company awaits the FDA's full letter within 30 days.